Literature DB >> 18635812

Combined functional and molecular analysis of tumor cell signaling defines 2 distinct myeloma subgroups: Akt-dependent and Akt-independent multiple myeloma.

Angela Zöllinger1, Thorsten Stühmer, Manik Chatterjee, Stefan Gattenlöhner, Eugenia Haralambieva, Hans-Konrad Müller-Hermelink, Mindaugas Andrulis, Axel Greiner, Carmen Wesemeier, Jörg C Rath, Hermann Einsele, Ralf C Bargou.   

Abstract

Although the phosphatidylinositide 3-kinase (PI3K)/Akt pathway has been reported to contribute to the malignant growth of multiple myeloma (MM), the true relevance of Akt kinases for this disease is still unclear. In particular, functional analyses in primary tumor cells and genetic target validation experiments are missing. Here, we used combined functional and molecular analyses to determine the importance of Akt activity in a large panel of primary MM samples and in MM cell lines. Akt down-regulation with isoform-specific siRNA constructs or with an Akt1/2-specific pharmacologic inhibitor strongly induced apoptosis in approximately half of the primary MM samples analyzed. Sensitivity to Akt inhibition strongly correlated with the activation status of Akt as determined by immunohistochemistry, phospho-Akt-specific flow cytometry, and Western analysis. Additional blockade of the MAPK and the IL-6R/STAT3 pathways was often not sufficient to decrease the viability of MM cells resilient to Akt inhibition. Taken together, these experiments led to the identification of 2 myeloma subgroups: Akt-dependent and Akt-independent MM.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18635812     DOI: 10.1182/blood-2007-11-119362

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  24 in total

Review 1.  Signaling Pathways and Emerging Therapies in Multiple Myeloma.

Authors:  Vijay Ramakrishnan; Anita D'Souza
Journal:  Curr Hematol Malig Rep       Date:  2016-04       Impact factor: 3.952

2.  The CD27+ memory B cells display changes in the gene expression pattern in elderly individuals.

Authors:  Alicia Báez; Isabel Alvarez-Laderas; José I Piruat; Teresa Caballero-Velázquez; M Victoria Barbado; Africa Millán-Uclés; Mayte Medrano; Estefanía García-Guerrero; Li Sánchez-Abarca; José Antonio Pérez-Simón
Journal:  Immunology       Date:  2014-09-06       Impact factor: 7.397

3.  Targeting TORC2 in multiple myeloma with a new mTOR kinase inhibitor.

Authors:  Bao Hoang; Patrick Frost; Yijiang Shi; Eileen Belanger; Angelica Benavides; Gholam Pezeshkpour; Susanna Cappia; Tommasina Guglielmelli; Joseph Gera; Alan Lichtenstein
Journal:  Blood       Date:  2010-08-04       Impact factor: 22.113

4.  Antimyeloma activity of the sesquiterpene lactone cnicin: impact on Pim-2 kinase as a novel therapeutic target.

Authors:  Karin Jöhrer; Marlene Obkircher; Daniel Neureiter; Johanna Parteli; Claudia Zelle-Rieser; Eva Maizner; Johann Kern; Martin Hermann; Frank Hamacher; Olaf Merkel; Nathalie Wacht; Christian Zidorn; Marcel Scheideler; Richard Greil
Journal:  J Mol Med (Berl)       Date:  2011-12-29       Impact factor: 4.599

5.  Cell adhesion down-regulates the expression of vacuolar protein sorting 4B (VPS4B) and contributes to drug resistance in multiple myeloma cells.

Authors:  Jie Tang; Lili Ji; Yuchan Wang; Yuejiao Huang; Haibing Yin; Yunhua He; Jing Liu; Xiaobing Miao; Yaxun Wu; Xiaohong Xu; Song He; Chun Cheng
Journal:  Int J Hematol       Date:  2015-03-25       Impact factor: 2.490

6.  The PI3K/Akt signaling pathway regulates the expression of Hsp70, which critically contributes to Hsp90-chaperone function and tumor cell survival in multiple myeloma.

Authors:  Manik Chatterjee; Mindaugas Andrulis; Thorsten Stühmer; Elisabeth Müller; Claudia Hofmann; Torsten Steinbrunn; Tanja Heimberger; Heike Schraud; Stefanie Kressmann; Hermann Einsele; Ralf C Bargou
Journal:  Haematologica       Date:  2012-10-12       Impact factor: 9.941

7.  Phospho-flow detection of constitutive and cytokine-induced pSTAT3/5, pAKT and pERK expression highlights novel prognostic biomarkers for patients with multiple myeloma.

Authors:  R Brown; S Yang; C Weatherburn; J Gibson; P J Ho; H Suen; D Hart; D Joshua
Journal:  Leukemia       Date:  2014-07-03       Impact factor: 11.528

8.  TIMP3 regulates osteosarcoma cell migration, invasion, and chemotherapeutic resistances.

Authors:  Xiu-Guo Han; Yan Li; Hui-Min Mo; Kang Li; Du Lin; Chang-Qing Zhao; Jie Zhao; Ting-Ting Tang
Journal:  Tumour Biol       Date:  2016-01-09

9.  Pan-Raf co-operates with PI3K-dependent signalling and critically contributes to myeloma cell survival independently of mutated RAS.

Authors:  E Müller; S Bauer; T Stühmer; A Mottok; C-J Scholz; T Steinbrunn; D Brünnert; A Brandl; H Schraud; S Kreßmann; A Beilhack; A Rosenwald; R C Bargou; M Chatterjee
Journal:  Leukemia       Date:  2016-09-30       Impact factor: 11.528

10.  Multiple mechanisms contribute to the synergistic anti-myeloma activity of the pan-histone deacetylase inhibitor LBH589 and the rapalog RAD001.

Authors:  Vijay Ramakrishnan; Teresa Kimlinger; Michael Timm; Jessica Haug; S Vincent Rajkumar; Shaji Kumar
Journal:  Leuk Res       Date:  2014-09-28       Impact factor: 3.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.